Literature DB >> 18475571

Immunoregulatory biological response modifiers: effect of cytokines on septic shock.

M A Chirigos1, C De Simone.   

Abstract

Whole bacteria or bacterial components or their extracts were employed to restore or augment the immune system. Beneficial effects were attained with these agents in treating various diseases. These agents were named biological response modifiers (BRMs) because they regulated certain cellular components of the immune system. The cellular regulation induced by these BRMs was found to be due to cytokines. The cytokines were shown to act directly on the various cellular components and to provide therapeutic benefit in various autoimmune and immune deficiency diseases. Overproduction of specific cytokines however leads to a deleterious effect on the host. Overproduction of tumour necrosis factor (endotoxin, lipopolysaccharide) leads to septic shock. Bacteraemia is the leading cause of overproduction of tumour necrosis factor (TNF). Septic shock in many cases leads to death. Several monoclonal antibodies to lipopolysaccharide (LPS) and anticytokines have demonstrated protection against septic shock.

Entities:  

Year:  1993        PMID: 18475571      PMCID: PMC2365442          DOI: 10.1155/S0962935193000675

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  36 in total

1.  T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens.

Authors:  I M Orme; E S Miller; A D Roberts; S K Furney; J P Griffin; K M Dobos; D Chi; B Rivoire; P J Brennan
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

2.  Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?

Authors:  T Matsuyama; N Kobayashi; N Yamamoto
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

3.  Evaluation of phagocyte functions, inflammatory lymphokine activities and in vitro antibody synthesis in patients with active and chronic pulmonary tuberculosis.

Authors:  S Antonaci; E Jirillo; A Polignano; M T Ventura; R Sabato; L Bonomo
Journal:  Cytobios       Date:  1991

4.  Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection.

Authors:  C M Mastroianni; F Paoletti; C Valenti; V Vullo; E Jirillo; S Delia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease.

Authors:  N Foley; C Lambert; M McNicol; N Johnson; G A Rook
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

6.  Human Mycobacterium tuberculosis-reactive CD4+ T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes.

Authors:  W H Boom; R S Wallis; K A Chervenak
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

7.  Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure.

Authors:  P F Barnes; D Chatterjee; J S Abrams; S Lu; E Wang; M Yamamura; P J Brennan; R L Modlin
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

8.  Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. Monocyte dependence and indomethacin reversibility.

Authors:  M E Kleinhenz; J J Ellner; P J Spagnuolo; T M Daniel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

9.  Cytokine dysregulation in AIDS: in vivo overexpression of mRNA of tumor necrosis factor-alpha and its correlation with that of the inflammatory cytokine GRO.

Authors:  B J Dezube; A B Pardee; L A Beckett; C M Ahlers; L Ecto; J Allen-Ryan; A Anisowicz; R Sager; C S Crumpacker
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

10.  Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study.

Authors:  E Jirillo; M Altamura; I Munno; N M Pellegrino; R Sabato; S Di Fabio; C De Simone
Journal:  Immunopharmacol Immunotoxicol       Date:  1991       Impact factor: 2.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.